Can fluoroquinolones be considered once-daily therapy?

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Fluoroquinolones are potent antimicrobial agents effective against Enterobacteriaceae.
• Current fluoroquinolones have half-lives allowing once-daily administration for specific infections.

Purpose of the Study:

• To evaluate the potential of newer fluoroquinolones for once-daily dosing in treating a broader range of infections.
• To assess the efficacy and safety of once-daily fluoroquinolone therapy.

Main Methods:

• Review of pharmacokinetic properties of fluoroquinolone antimicrobial agents.
• Analysis of in vitro activity against Gram-positive and Gram-negative bacteria.
• Consideration of clinical study requirements for once-daily dosing efficacy.

Main Results:

• Fluoroquinolones inhibit most Enterobacteriaceae at very low concentrations (≤0.5 µg/mL).
• Newer agents exhibit enhanced activity against Gram-positive organisms (≤1 µg/mL) and longer half-lives.
• Potential for once-daily use in respiratory, skin, and bone infections.

Conclusions:

• Once-daily fluoroquinolone therapy holds promise for improved cost-effectiveness and patient compliance.
• Further clinical studies are crucial to confirm efficacy, compare with multiple dosing, and monitor resistance development.
• Optimizing fluoroquinolone dosing regimens can enhance treatment outcomes.